Interés Humano

Tercera dosis de vacuna contra la covid–19 de Pfizer tiene 95,6% de eficacia

Firma realizó estudio con 10.000 mayores de 16 años

(FILES) In this file photo taken on February 02, 2021 a health worker holds a vial with the Pfizer-BioNTech COVID-19 vaccine against the coronavirus at the vaccination center in Freising, southern Germany. - A booster shot of the anti-Covid-19 vaccine developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection, according to trial data published by the makers on October 21, 2021. The clinical phase three trial with "10,000 participants 16 years of age and older" showed "a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain", the companies said in a statement. (Photo by Christof STACHE / AFP)
(FILES) In this file photo taken on February 02, 2021 a health worker holds a vial with the Pfizer-BioNTech COVID-19 vaccine against the coronavirus at the vaccination center in Freising, southern Germany. - A booster shot of the anti-Covid-19 vaccine developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection, according to trial data published by the makers on October 21, 2021. The clinical phase three trial with "10,000 participants 16 years of age and older" showed "a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain", the companies said in a statement. (Photo by Christof STACHE / AFP) CHRISTOF STACHE
‌
‌

‌

‌
‌

‌

‌